• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Lexeo Therapeutics Inc.

    4/28/25 4:47:27 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LXEO alert in real time by email
    DEFA14A 1 defa14a_2024.htm DEFA14A DEFA14A

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
    SECURITIES EXCHANGE ACT OF 1934

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to §240.14a‑11(c) or §240.14a‑2

    LEXEO THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table below per Exchange Act Rules 14a‑6(i)(4) and 0‑11.

     

     


     

    img243671805_0.jpg


     

    img243671805_1.jpg

     

    Your Vote Counts! LEXEO THERAPEUTICS, INC. 2025 Annual Meeting Vote by June 25, 2025 11:59 PM ET LEXEO THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, FLOOR 6 NEW YORK, NY 10010 V74336-P33097 You invested in LEXEO THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 26, 2025. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by submitting your request prior to June 12, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 26, 2025 10:00 AM ET Virtually at: www.virtualshareholdermeeting.com/LXEO2025 *Please check the meeting materials for any special requirements for meeting attendance. Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items 1. The election of Steven Altschuler and Reinaldo Diaz as Class II directors. Nominees: 1a. Steven Altschuler For 1b. Reinaldo Diaz For 2. The ratification of the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025. For NOTE: In their discretion, the proxyholders will vote on such other business as may properly come before the meeting or any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V74337-P33097


    Get the next $LXEO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LXEO

    DatePrice TargetRatingAnalyst
    6/13/2024$28.00Outperform
    Robert W. Baird
    6/6/2024$22.00Buy
    H.C. Wainwright
    11/28/2023$20.00Overweight
    JP Morgan
    11/28/2023$20.00Buy
    Stifel
    11/28/2023$19.00Outperform
    Leerink Partners
    11/28/2023$22.00Outperform
    RBC Capital Mkts
    11/28/2023$23.00Buy
    Chardan Capital Markets
    More analyst ratings

    $LXEO
    Financials

    Live finance-specific insights

    See more
    • Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

      Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well tolerated across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA) Company to host webcast today at 7:00 AM ET NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced positive interim results from the Phase 1/2 study of LX1001

      10/30/24 6:14:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

      NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical

      7/11/24 8:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    SEC Filings

    See more

    $LXEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lexeo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)

      5/27/25 7:32:57 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

      SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      5/15/25 9:58:26 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

      SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      5/14/25 12:00:47 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Lexeo Therapeutics with a new price target

      Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00

      6/13/24 7:10:25 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Lexeo Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $22.00

      6/6/24 7:17:54 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan initiated coverage on Lexeo Therapeutics with a new price target

      JP Morgan initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $20.00

      11/28/23 7:29:52 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

      Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entered into a securities purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 20,790,120 shares ("Shares") of its common sto

      5/27/25 7:31:10 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

      Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently enrolling patients in Cohort 3; interim clinical data update on track for second half of 2025 Redeployed $20 million to focus on clinical-stage programs; cash, cash equivalents and investments of $106.9 million expected to prov

      5/12/25 7:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

      NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, LA. "The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality," said José Manuel Otero, Chief Technical Officer of Lexeo Therapeutics. "Scientists at Lexeo have optimized a manufacturing platfo

      5/1/25 9:16:04 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cholmondeley Paula H bought $104,852 worth of shares (15,000 units at $6.99), increasing direct ownership by 96% to 30,627 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      11/26/24 5:00:06 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Leadership Updates

    Live Leadership Updates

    See more
    • Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

      NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs. "Kyle has an exceptional track record as an operator and life sciences portfolio manager, and we are excited to welcome him to Lexeo at a time when we are advancing our pipeline and tran

      12/19/24 7:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

      Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/

      11/13/24 7:30:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

      Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N

      8/12/24 7:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Adler Eric sold $1,623 worth of shares (585 units at $2.77), decreasing direct ownership by 0.86% to 67,681 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      5/20/25 5:00:14 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Legal Officer Robertson Jenny sold $1,445 worth of shares (521 units at $2.77), decreasing direct ownership by 0.82% to 63,098 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      5/20/25 5:00:12 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Townsend Richard Nolan sold $2,979 worth of shares (1,074 units at $2.77), decreasing direct ownership by 0.48% to 221,173 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      5/20/25 5:00:15 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

      SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      11/14/24 5:49:30 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

      SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      11/14/24 4:45:58 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

      SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      11/14/24 12:32:15 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care